Clinical Trial

A Study to Evaluate the Efficacy and Safety of Fixed-Dose Combination of Pitavastatin/Ezetimib

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated September 12, 2025 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to evaluate the efficacy and safety of fixed-Dose combination of Pitavastatin/Ezetimibe under the real-world condition
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-03-11; most recent amendment 2025-09-10.
Status change: Not Yet Recruiting → Recruiting 2024-04-22
Trial Details
NCT Number NCT06314919
Lead Sponsor Boryung Pharmaceutical Co., Ltd
Conditions Primary Hypercholesterolemia, Mixed Dyslipidemia
Enrollment 8,606 participants
Start Date 2024-03-15
Primary Completion 2026-06 (estimated)
Study Completion 2026-06 (estimated)
Updated on ClinicalTrials.gov 2025-09-12